Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | UCART20X22 |
Synonyms | |
Therapy Description |
UCART20X22 consists of a preparation of allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both CD20 and CD22, which potentially leads to antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 551). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
UCART20X22 | UCART-20x22|UCART 20x22 | CD20 Immune Cell Therapy 11 CD22 Immune Cell Therapy 15 | UCART20X22 consists of a preparation of allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both CD20 and CD22, which potentially leads to antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 551). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05607420 | Phase Ib/II | Alemtuzumab UCART20X22 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) | Recruiting | USA | FRA | ESP | 0 |